Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of TG Therapeutics Inc (NASDAQ: TGTX) closed at $34.04 in the last session, up 0.68% from day before closing price of $33.81. In other words, the price has increased by $0.68 from its previous closing price. On the day, 1.9 million shares were traded. TGTX stock price reached its highest trading level at $34.735 during the session, while it also had its lowest trading level at $33.36.
Ratios:
We take a closer look at TGTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.96 and its Current Ratio is at 3.86. In the meantime, Its Debt-to-Equity ratio is 0.42 whereas as Long-Term Debt/Eq ratio is at 0.42.
On October 29, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $50.TD Cowen initiated its Buy rating on October 29, 2024, with a $50 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 11 ’25 when Lonial Sagar sold 20,852 shares for $32.24 per share. The transaction valued at 672,268 led to the insider holds 94,061 shares of the business.
Lonial Sagar bought 20,852 shares of TGTX for $672,233 on Sep 11 ’25. On Jun 13 ’25, another insider, Echelard Yann, who serves as the Director of the company, sold 10,000 shares for $36.94 each. As a result, the insider received 369,400 and left with 228,816 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 5400977920 and an Enterprise Value of 4968939520. As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.24, and their Forward P/E ratio for the next fiscal year is 18.45. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.08. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.15 while its Price-to-Book (P/B) ratio in mrq is 19.46. Its current Enterprise Value per Revenue stands at 9.342 whereas that against EBITDA is 48.323.
Stock Price History:
The Beta on a monthly basis for TGTX is 2.01, which has changed by 0.211828 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, TGTX has reached a high of $46.48, while it has fallen to a 52-week low of $23.60. The 50-Day Moving Average of the stock is 0.84%, while the 200-Day Moving Average is calculated to be -2.59%.
Shares Statistics:
According to the various share statistics, TGTX traded on average about 2.12M shares per day over the past 3-months and 2224100 shares per day over the past 10 days. A total of 158.67M shares are outstanding, with a floating share count of 142.92M. Insiders hold about 9.92% of the company’s shares, while institutions hold 63.59% stake in the company. Shares short for TGTX as of 1760486400 were 23810220 with a Short Ratio of 11.24, compared to 1757894400 on 24587257. Therefore, it implies a Short% of Shares Outstanding of 23810220 and a Short% of Float of 19.629999.
Earnings Estimates
A comprehensive evaluation of TG Therapeutics Inc (TGTX) is underway, with the input of 5.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.37, with high estimates of $0.39 and low estimates of $0.34.
Analysts are recommending an EPS of between $3.07 and $2.44 for the fiscal current year, implying an average EPS of $2.83. EPS for the following year is $2.05, with 5.0 analysts recommending between $2.56 and $1.74.
Revenue Estimates
According to 7 analysts,. The current quarter’s revenue is expected to be $181.39M. It ranges from a high estimate of $187.66M to a low estimate of $176.9M. As of. The current estimate, TG Therapeutics Inc’s year-ago sales were $108.19MFor the next quarter, 7 analysts are estimating revenue of $195.39M. There is a high estimate of $209.5M for the next quarter, whereas the lowest estimate is $187.3M.
A total of 7 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $611.38M, while the lowest revenue estimate was $600.6M, resulting in an average revenue estimate of $605.03M. In the same quarter a year ago, actual revenue was $329MBased on 8 analysts’ estimates, the company’s revenue will be $901M in the next fiscal year. The high estimate is $955.86M and the low estimate is $847.5M.
